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Summary 
Chronic lymphocytic leukemia (CLL) B cells are hyporesponsive or refractory to mitogens and 
growth factors in vitro. This study examined whether transforming  growth factor 3  (TGF-13), 
a potent inhibitor of lymphocyte proliferation may play a role in the growth regulation of CLL 
B cells. CLL B cells from all donors treated expressed detectable TGF-31 mRNA. In vitro release 
of  TGF-/3  by  unstimulated  cultures,  or  cultures  stimulated  by  antibody  to  cell  surface 
immunoglobulin  (anti-#) plus phorbol 12-myristate 13-acetate (PMA) was higher in CLL than 
in normal B cells. High levels of TGF-13 activity were also detected in plasma samples of CLL 
patients.  The role of TGF-13 in growth regulation  of CLL B cells was tested in assays using 
different B cell activators. Purified neoplastic B cells from most CLL patients proliferated in response 
to anti-/~,  or the combination of anti-/~ plus PMA. Levels of CLL B cell proliferation were lower 
than observed in normal B cells. Some CLL were refractory to these stimuli. Antibody to CD40 
induced proliferation of CLL B cells from all donors tested when presented on FcyRII (CDw32)- 
expressing L cells. Neutralizing  antibodies to TGFq3 increased CLL B cell proliferation in the 
absence or presence of additional stimuli. These effects were dose dependent and specific. Exogenous 
TGF-3 completely inhibited CLL B cell proliferation induced by anti-#, PMA, and anti-TGF-13. 
CLL B cell proliferation induced by anti-CD40  was reduced by exogenous TGF-13.  However, 
even at high doses, TGF-3 did not completely inhibit the anti-CD40 effect. In summary, TGF-3 
is overexpressed in CLL. CLL B cells are sensitive to TGF-13 and this cytokine functions as an 
autocrine growth inhibitor accounting at least in part for reduced proliferative responses of these 
leukemic cells  and for the  slow progression  of the malignant  process in vivo. 
T 
umor cells are often resistant to signals that inhibit growth 
of their normal cell counterparts. Escape from such con- 
trol mechanisms  may contribute to malignant  transforma- 
tion. Proliferation of normal B cells is controlled in part by 
the endogenous production of growth inhibitors.  TGF-3 is 
a potent immunosuppressive factor and inhibitor  of B cell 
proliferation (1). Normal B cells express TGF-13 and neutral- 
ization of endogenous TGF-3 results in enhanced B cell re- 
sponses.  Chronic  lymphocytic leukemia  (CLL)  B cells  are 
characterized by a very small percentage of peripheral blood 
and bone marrow cells in S phase (2). In vitro proliferation 
of CLL B cells is heterogeneous but generally characterized 
by hyporesponsiveness  to stimulation with mitogens, Epstein- 
Barr virus (EBV) or cytokines (3).  Low levels of CLL B cell 
proliferation  can be induced by combinations of some mitogens 
or cytokines, such as IL-2, TNF, and IL-7 (4-7). Antibody 
to CD40 recently has been shown to stimulate proliferation 
in CLL B cells from most patients (8). These studies suggest 
that the hyporesponsiveness of CLL B cells may be the con- 
sequence of regulatory events rather than irreversible  changes 
that are characteristic of other transformed cell types. How- 
ever,  regulatory pathways  that  may be responsible for the 
anergy of CLL B cells have not been identified. Furthermore, 
it is not clear whether this leukemic cell type is sensitive to 
the growth inhibitory effects of TGFq3 (9).  The objective 
of the present study was to analyze the potential contribu- 
tion of TGF-13 to  the hyporesponsiveness of CLL B cells. 
Materials and Methods 
Cells.  Peripheral blood samples were obtained from 18 patients 
fulfilling diagnostic and immunophenotypic  criteria for common 
B cell CLL at the University of California at San Diego, Medical 
Center, the Veteran's Administration Hospital or the Scripps Clinic 
and Research Foundation (all in La Jolla, CA) (10-14). The median 
age of the patients was 66, ranging from 59 to 77 yr. The patients 
were heterogeneous with respect to clinical stage (ranging  from 
Rai stage 0 to stage IV) and prior therapy for CLL.  14 (78%) of 
the patients were male, reflecting the known 2:1 male/female prev- 
alence of common CLL (15). 
Direct immunofluorescence analyses of the mononuclear  cells 
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cating that >90% (median, 99%) of the lymphocytes  in each sample 
coexpressed pan-B cell surface  antigens, CD5, and r or )x light chains 
(not shown). Of the 18 leukemia cell populations studied, 8 (44%) 
expressed Ig g light chains and 10 (56%) expressed X light chains. 
Normal B cells were isolated from peripheral blood of healthy 
volunteers. 
Proliferation Assays.  Proliferation studies were performed in 96- 
well flat bottom plates with 50,000 cells/well in RPMI 1640 sup- 
plemented with 5% FBS, t-glutamine, and antibiotics. Cells were 
pulsed with [3H]thymidine (1/~Ci/well) during the final 18 h of 
a 5-d culture and collected on an automated cell harvester. Radio- 
activity incorporated by the cells was quantified by liquid scintilla- 
tion counting.  Experiments on B cell responses to  anti-CD40 
were performed in  96-well, flat-bottom  plates in  RPMI  1640 
supplemented with 10%  FBS, t-glutamine,  and antibiotics. 104 
CDw32-L cells (kindly provided by Dr. Kevin Moore, DNAX, 
Palo Alto, CA) and 10  s CLL-B  cells per well were added with anti- 
CD40 mAb G28-5 at various concentrations with and without 
recombinant human IL-4 as described (16). The cells were pulsed 
with I #Ci/well [3H]thymidine  for the final 18 h of a 5-d culture. 
The results obtained with [3H]thymidine incorporation were 
confirmed in studies where TCR-precipitated DNA from cell cul- 
tures was quantified. 
Monocyte and T cell depletion were performed by incubation 
of PBMC with antibodies to CD3 (OKT3) and CDllc (LeuMS). 
Monocytes and T cells were then removed with goat anti-mouse 
antibody coupled to magnetic beads. 
7GF-fl Assays.  TGF-/3  content in CLL plasma and conditioned 
media was quantified in the CLL64 and the lymphocyte activating 
factor assays as described (17). 
Antibodies and Cytokines.  Anti-TGF-~,  rabbit or mouse and 
species-specific  control Ab, and recombinant human TGF-~I (R&D 
Systems Inc., Minneapolis, MN); goat anti-human IgM F(ab)z Ab 
and control  F(ab)2 (Cappel Research Products, Durham,  NC); 
anti-CD40 mAb G28-5 (18) was a gift from Dr. Edward Clark, 
University of Washington, Seattle, WA; MOPC 21 (murine IgGl; 
Cahag, Inc., South San Francisco, CA); recombinant human IL4 
was purchased from Biosource International (Camarillo, CA). 
Results 
TGF-fl Production In  Vitro and Levels in Plasma.  TGF-~ 
expression by CLL B cells was analyzed in the presence and 
absence of in vitro stimulation. Most of the TGF-B activity 
secreted by normal or CLL B cells was in latent form. The 
mean levels of TGF-/5 released from unstimulated CLL B cell 
preparations were approximately twofold higher as compared 
with normal B cells. The combination of anti-/x plus PMA 
increased TGF-/3 activity 2.8-fold in normal and 4.4-fold in 
CLL B cells (Fig.  1). TGF-/~I mRNA was present in high 
levels in all CLL B cell preparations and there were no de- 
tectable differences between the 10 patients that were tested 
(not shown). These results suggest that CLL B cells release 
more  TGF-/5  than  normal  B  cells  and  confirm  a  recent 
study (9). 
Analysis of plasma showed that all of the 12 CLL samples 
contained >  1 ng/ml of TGF-/~. Most of the TGF-/3 activity 
was in latent form but active TGF-~ was detectable in 10/12 
patients. Plasma samples from 20 normal volunteers contained 
a mean level of 1.3 ng/ml of total TGF-~ activity. 
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Figure  1.  TGF-/3  production by CLL B cells. TGF was tested in 24-h 
conditioned media from CLL (n = 8) and normal (n = 5) B cells that 
were either unstimulated (control) or stimulated  with anti-# or anti-# 
plus PMA. Samples  were tested after  transient  acidification  in the CCL64 
assay. 
Neutralization of TGF-fl Activity Causes Increased CLL B 
Cell Proliferation.  CLL B cell proliferation induced by anti- 
body to cell surface immunoglobulin (anti-/x) alone or in com- 
bination with PMA was reduced as compared with normal 
B cells (Fig. 2 A). B cells from some CLL patients were refrac- 
tory to stimulation with combinations of these agents (Fig. 
2 E). To test whether TGF-B is involved with the reduced 
proliferative responses  of CLL B cells, we used antibodies 
that neutralize the biological activity of TGF-/~. These anti- 
bodies increased  CLL B  cell  proliferation.  In  some cases, 
proliferation was increased  in the absence of other stimuli 
(Fig. 2 B), while in most CLL B cell populations the pres- 
ence of anti-# and or PMA was required (Fig. 2, C and D). 
CLL B cells that did not proliferate in response to anti-/x and 
PMA also failed to respond when anti-TGF-/5 was included 
(Fig. 2 E). The TGF-/3 antibody effects were dose dependent 
and specific. Stimulation was observed with antibodies from 
three different species (rabbit, chicken, and mouse) and the 
increases in CLL proliferation were directly related to their 
neutralizing titers.  CLL B cells prepared from the different 
patients showed one of these four patterns of  in vitro prolifer- 
ative responses  as shown in Fig. 2, B-E. These patterns of 
CLL B cell responses to stimulation with mitogens of anti- 
bodies to TGF-B did not correlate with the clinical stage of 
the patients (data not shown). To determine whether the anti- 
TGF-~ effects were indeed on the CLL B cells, we stained 
the cell populations for the expression ofidiotypes that char- 
acterize  the CLL B cell clones.  These experiments showed 
that after a 5-d culture in the presence of antibody to TGF-/3 
the cell populations were >97%  idiotype positive. 
CLL B Cell Proliferation Induced by Anti-CD40.  All CLL 
B cells tested in the present study proliferated to anti-CD40 
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Figure  2.  Neutralization  of endogenous TGF-fl and CLL B cell prolifer- 
ation. CLL  B cells were incubated with TGF-fl neutralizing rabbit IgG 
(a-TGF-fl) at 1 or 10/~g/ml or preimmune control rabbit IgG (ctr IgG) 
at 1 or 10/~g/ml, anti-/z or PMA in microtiter wells for 96 h. The cells 
were pulsed with [3H]thymidine during the final 12-16 h and then col- 
lected on an automated cell harvester. Incorporation  of radioactivity was 
quantified by liquid scintillation counting.  Four patterns of CLL B cell 
responses were observed and the results from individual donors representing 
the individual  patterns  are shown. 
presented on L cells expressing the human Fc3'RII (CD32) 
in the absence or presence of IL-4. The magnitude of prolifer- 
ation induced by anti-CD40 was greater than that induced 
by the other stimuli.  Even those CLL B cells that did not 
respond to the other stimuli (CLL4) were induced to proliferate 
(Fig. 3). This group of CLL B cells also responded to TGF-3 
antibodies in combination  with suboptimal concentrations 
of anti-CD40 (Fig. 3). These findings suggest that all CLL 
B cell populations respond with increased proliferation to neu- 
tralizing antibody to TGF-3 despite their heterogeneity  in 
responsiveness to anti-/~ and PMA. 
Inhibition  of  CLL  B  Cell  Proliferation  by  Exogenous 
7GF-fl.  Results  obtained from studies with TGF-3 neu- 
tralizing antibody indirectly suggested that CLL B cells can 
be growth inhibited by TGF-3. To test TGF-fl responsive- 
ness of CLL B cells directly, cells were stimulated with anti- 
TGF-fl or anti-~ plus anti-TGF-3  or PMA and cultured in 
the presence of exogenous TGFq3. Recombinant human TGF- 
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Figure  3.  Neutralizing antibodies to TGF-fl augment anti-CD40-in- 
duced proliferation of CLL B cells. 10  s CLDB cells were cultured on a 
monolayer of CDw32-L cells in the presence of I #g/ml anti-CD40 mAb 
and 10 ng/ml rhlL-4 and increasing concentrations of rabbit anti-human 
TGF-3 mAb (closed squares) or control rabbit Ig (open squares) were added 
at the initiation of cultures as indicated on the abscissa. Proliferation was 
measured during the final 18 h of a 5-d culture as cpm of incorporated 
[3H]thymidine. Data points, means of triplicate wells, error bars, SD. 
fll completely blocked the stimulatory effects of anti-TGF-fl 
antibody as well as proliferation induced by anti-# or anti-# 
plus PMA (Fig. 4) with an EDs0 between 0.1 and 1 ng/ml. 
Anti-CD40  induced proliferation also is reduced by exoge- 
nous TGF-fl in all cases (Fig. 4 B).  However, even at high 
concentrations, TGF-3 cannot completely inhibit prolifera- 
tion induced by CD40 cross-linking.  In experiments with 
optimal concentrations of anti-CD40 in the absence or pres- 
ence of IL-4, we observed an average 52.9% (_+ 24.7 SD) in- 
hibition with maximal doses of TGF-fll (10-20 ng/ml). Com- 
plete inhibition  by TGF-fl was  not  observed in  any of 12 
separate experiments using cells from 6 different CLL patients. 
Discussion 
The present study shows that CLL B cells produce TGF-fl 
in vitro and that plasma samples from CLL patients contain 
increased levels of TGF-fl. B cells from all CLL patients tested 
in this study were sensitive to growth inhibition by TGF-3. 
Endogenously produced TGF-fl serves as an autocrine growth 
inhibitor of CLL B cells. Increased proliferation was induced 
by antibody  to TGF-fl in all cases of CLL B  cells. 
In vitro proliferative responses of CLL B  cells from the 
different patients  in  the present  series were heterogeneous 
as observed in most previous studies (19, 20). Heterogeneity 
was observed in the responses to stimulation with anti-# and 
PMA. CLL B cells from some donors responded to a single 
stimulus whereas others proliferated only when treated with 
several stimuli. The effect of CD40 cross-linking was quali- 
tatively uniform. CLL B cells from all donors tested responded 
to anti-CD40.  The magnitude  of the anti-CD40  response 
was greater than the effect of the other stimuli,  and varied 
among the different patients, but the levels of the responses 
to anti-CD40  and  the other  stimuli correlated. 
TGF-fl appears to function as an endogenous growth in- 
hibitor in CLL, since neutralizing antibodies increased prolifer- 
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Figure  4.  Exogenous  TGF-fl and CLL B ce|l proliferation. (A) Exoge- 
nous TGF-fl completely inhibits proliferation induced by anti-#, PMA, 
and anti-TGF-fl. CLL B cells were stimulated with antibodies to TGF-fl 
in the presence or absence to anti-/,. Recombinant TGF-31 (10 ng/ml) 
was added at the initiation of a 5-d culture. (B) Exogenous TGF-fl does 
not completely inhibit anti-CD40-induced proliferation of CLL B cells. 
10  s CLL B cells were cultured on a monolayer of CDw32-L cells in the 
presence of 1 #g/ml MOPC 21 control murine IgG (open squares) or anti- 
CD40 mAb (closed squares). Increasing concentrations of human TGF-fll 
were added at the initiation of cultures as indicated  on the abscissa. Prolifer- 
ation was measured during the final 18 h of a 5-d culture as counts per 
minute of incorporated [3H]thymidine. Data points are means of tripli- 
cate wells. The proliferation measured at all concentrations of exogenous 
TGF-fl plus anti-CD40 is significantly higher than that observed in the 
presence of control mAb and CDw32-L cells (p ~<0.03). 
ation in all cases. In some cases TGF-3-neutralizing antibodies 
caused increased proliferation in the absence of other added 
stimuli,  suggesting  that  these CLL B  cells are sufficiently 
activated to enter S-phase and that this is prevented by en- 
dogenous TGF-fl. This is in contrast to normal B cells where 
antibodies to TGF-fl do not increase proliferation in the ab- 
sence of mitogens.  In other cases of CLL anti-TGF-fl aug- 
mented the reduced proliferative responses to mitogens and 
growth factors, suggesting that, in the context of appropriate 
stimulation,  in vivo proliferative responses  are reduced by 
TGF-fl.  There were no apparent  correlations between the 
magnitude  of the proliferative responses,  the response pat- 
terns to anti-TGF-fl and clinical variables in a retrospective 
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be more appropriate to formally address  this question. 
The results obtained with antibodies to TGF-3 suggested 
that these leukemic B cells are sensitive to the antiprolifera- 
tive effects of this cytokine. Direct evidence for this was ob- 
tained in studies where proliferation induced by anti-/z  or 
anti-/z and PMA was  completely inhibited by exogenous 
TGF-3. 
The proliferative response to anti-CD40 also was reduced 
in a dose-dependent fashion. However, complete inhibition 
was never observed.  Even in the presence of the highest con- 
centrations of TGF-3 there was significant residual prolifera- 
tion. This partial resistance  of the anti-CD40 proliferative 
effect is consistent with a recent study that showed that anti- 
CD40 can override the TGF-3 inhibition of CD23 expres- 
sion (21). As CLL B cell proliferation induced by stimuli other 
than CD40 cross-linking is inhibited by TGF-~, a factor ex- 
pressed in CLL, it is conceivable  that stimulation through 
CD40 may be the primary mechanism driving expansion of 
these cells in vivo.  Cross-linking of CD40 induces pheno- 
typic changes on CLL B cells in vitro which are not seen 
on leukemic B cells isolated from peripheral blood of CLL 
patients (16). Identification of anatomical sites other than blood 
where CD40 ligand is expressed as well as the precise loca- 
tion where CLL B cells proliferate in vivo will advance this 
hypothesis. 
The present results indicate that TGF-3 is present at in- 
creased circulating levels in CLL patients and that this may 
originate from the tumor cells. Patients with this leukemia 
have signs of impaired immune function as indicated by de- 
fective delayed-type hypersensitivity reactions, autoimmune 
phenomena, and an increased frequency of secondary malig- 
nancies. It is possible that the increased levels of TGF-3 con- 
tribute to these defects and also may impair the immune re- 
sponses  to these tumor cells. Overexpression of TGF-3 in 
other conditions such as glioblastoma, adult T cell leukemia 
(ATL) (22),  and HIV infection (23) has been suggested to 
lead to immunosuppression. 
The findings from the present study provide new insight 
into the pathogenesis of CLL and define a negative autocrine 
circuit that is responsible for some of the functional charac- 
teristics of CLL B cells in vitro and may influence the course 
of the disease process  in vivo. 
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